GLAXOSMITHKLINE PLC Form 6-K November 18, 2009

## FORM 6-K

# SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

**Report of Foreign Issuer** 

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending November 2009

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

\_-

#### **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return: From: 1 May 2009 To: 30 October 2009

Balance of unallotted securities under scheme(s) from 5,295,707

previous return:

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any 0

increase has been applied for):

Less: Number of securities issued/allotted under

scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

268,191

5,027,516

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline Share Option Plan - ADS

Period of return: From: 1 May 2009 To: 31 October 2009

Balance of unallotted securities under scheme(s) from

previous return: 6,389,424

2

*Plus:* The amount by which the block scheme(s) has

been increased since the date of the last return (if any 0

increase has been applied for):

Less: Number of securities issued/allotted under

scheme(s) during period (see LR3.5.7G):

363,648

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

6,025,776

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

#### **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: Glaxo Wellcome UK Share Option Scheme

Period of return: From: 1 May 2009 To: 31 October 2009

Balance of unallotted securities under scheme(s) from previous return: 5,119,750

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any 0

increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period: 5,119,750

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

#### **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: Glaxo Wellcome International Share Option Scheme

Period of return: 1 May 2009 To: 31 October 2009 From:

Balance of unallotted securities under scheme(s) from 13,267,156 previous return:

Plus: The amount by which the block scheme(s) has 0

been increased since the date of the last return (if any increase has been applied for):

Less: Number of securities issued/allotted under 0 scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

13,267,156

Name of contact: Victoria Whyte 020 8047 5000 Telephone number of contact:

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: Glaxo Wellcome 1999 Share Option Plan

Period of return: 1 May 2009 To: 31 October 2009 From:

0

0

Balance of unallotted securities under scheme(s) from 1,040,000

previous return:

*Plus:* The amount by which the block scheme(s) has

been increased since the date of the last return (if any

increase has been applied for):

Less: Number of securities issued/allotted under

scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

1,040,000

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an *ris*.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan -

Approved - Ordinary Shares

Period of return: From: 1 May 2009 To: 31 October 2009

Balance of unallotted securities under scheme(s) from 163,606

previous return:

*Plus:* The amount by which the block scheme(s) has been increased since the date of the last return (if any

increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

0

0

163,606

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan -

0

Unapproved - ADS

Period of return: From: 1 May 2009 To: 31 October 2009

Balance of unallotted securities under scheme(s) from

previous return:

*Plus:* The amount by which the block scheme(s) has been increased since the date of the last return (if any

increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

0

275,420

275,420

Name of contact: Victoria Whyte Telephone number of contact: 020 8047 5000

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan -

0

**Unapproved - Ordinary** 

Period of return: From: 1 May 2009 To: 31 October 2009

Balance of unallotted securities under scheme(s) from

previous return:

100,000

*Plus:* The amount by which the block scheme(s) has

been increased since the date of the last return (if any

increase has been applied for):

Less: Number of securities issued/allotted under

scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

100,000

Name of contact: Victoria Whyte 020 8047 5000 Telephone number of contact:

## **BLOCK LISTING SIX MONTHLY RETURN**

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 18 November 2009

Name of *applicant*: GlaxoSmithKline plc

Name of scheme:

Period of return: 31 October 2009 1 May 2009 To: From:

Balance of unallotted securities under scheme(s) from

previous return:

*Plus:* The amount by which the block scheme(s) has been increased since the date of the last return (if any 0

increase has been applied for):

Less: Number of securities issued/allotted under

scheme(s) during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted

at end of period:

GlaxoSmithKline Savings Related Share Option Scheme

5,264,981

73,735

5,191,246

Name of contact: Victoria Whyte 020 8047 5000 Telephone number of contact:

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: November 18, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc